Why Would Anyone Lend to a Startup That Is Losing Money?
This series examines venture lending to innovative startups: loans made to companies whose products, patents, or growth plans may be valuable in the future even though current profits are absent. The immediate question is not whether these companies are risky. They plainly are. The useful question is how a lender can decide that the risk is understandable enough to price and contract around. By the end of this explanation, you should be able to distinguish a company with no current profit from a company with no credible path to repayment, and to see which people, assets, and contract terms make that distinction possible.
The subject matters because startup finance is often described as if it has only two stages. First comes equity, which absorbs uncertainty in exchange for ownership. Much later comes ordinary bank debt, supported by cash flow and tangible assets. In between sits a less visible market: venture debt. It can give a young company time to finish research, reach a commercial milestone, or postpone another equity round. But it does not make risk disappear. It changes who carries the risk, what protects the lender, and how much time the company has to turn an uncertain prospect into a financeable business.
Why conventional debt looks like the wrong tool
A conventional loan asks for repayment on a schedule. A lender therefore needs more than an appealing idea. They need a reasonable basis for believing that the borrower will have cash when payments fall due, or that the lender can recover enough value if the plan fails. A young innovation company may have neither of the usual forms of reassurance. It may be spending heavily on research, have little equipment or property, and be years away from stable revenue. Its most important assets may be software, designs, patents, or specialized knowledge—things that are difficult to value before success and difficult to sell after failure.
Commercialization also creates a special information problem. The founders know more about the technology, the product’s weaknesses, and the likelihood of reaching a milestone than an outside lender does. The lender may struggle to tell a temporarily cash-burning company from one whose prospects were overstated. Once money is advanced, the effort needed to build the product or manage the company is not always visible. A borrower could delay hard work, spend too aggressively, or change direction in ways that make repayment less likely. These are not merely accounting gaps. They are contracting problems: the future depends on actions and events that are hard to specify in a loan agreement and hard to monitor perfectly afterward.
That is why equity is a natural early source of capital. An equity investor shares in the upside and does not demand fixed repayment while the company is still proving itself. The investor can accept that many projects will fail because a small number of successes may compensate for the losses. Debt has a different shape. Its upside is usually limited, so the lender must protect against the downside through information, collateral, pricing, covenants, or a credible expectation that someone else will help the company reach repayment.
The apparent contradiction—borrowing before profit—is therefore narrower than it first appears. “Not profitable” describes the company’s current income statement. It does not by itself answer four other questions: Is there a plausible future source of cash? Has someone informed and capable selected and monitored the company? Can an asset retain value outside the company? And does the contract give the business enough time to reach the event that makes repayment possible? Venture lending exists in the space where the answers are incomplete but not empty.
What venture debt is buying the company time to do
Venture debt is generally positioned after one or more venture-capital rounds and before a company is ready for ordinary senior debt. It is not a replacement for the equity that absorbs the earliest uncertainty. Nor is it simply a conventional bank loan offered to a business with normal cash flow. It is a bridge across a particular interval: the company has enough evidence to attract professional investors and has a growth plan, but its revenue, assets, or profitability have not yet caught up with its financing needs.
The attraction for founders and existing shareholders is straightforward. New equity brings cash, but it also reduces the ownership percentage of people who already hold shares. A loan can extend the financial runway without an immediate new equity issuance. That extra time may allow a startup to complete development, expand sales, wait for a better valuation, or absorb a delay without raising capital at the worst possible moment. In the EIB’s description of its product, venture debt is intended for research-focused and fast-growing companies whose payment obligations can be deferred or partly linked to performance. Its longer maturity is meant to give research and development more time to produce commercial returns.
The benefit is not free. A loan creates a claim that must be honored even when the company’s future remains uncertain. Interest and principal eventually compete with research, hiring, and marketing for the same cash. If the next equity round is delayed, the bridge can become a wall: the company may have to raise money under pressure, accept unfavorable terms, or default. A lender may also have rights over company assets, including patents. Specialized non-bank lenders may offer larger and riskier packages at higher rates, while banks may offer smaller loans and earn additional revenue from financial services. These differences reflect the risks and monitoring arrangements of the lenders; they do not turn venture debt into a safe asset.
The basic path can be represented simply:
The diagram’s important feature is the conditional arrow after the loan. Venture debt is useful when the extra time increases the chance of reaching a productive milestone or a credible refinancing event. The intended repayment source may be future revenue or a later financing round; it is not necessarily today’s profit. But if that event does not arrive, the lender needs a recovery route, and the borrower bears the cost of having pledged assets or promised payments.
This is why the timing of a loan matters as much as its headline interest rate. A company that has just received a substantial equity infusion may have cash, investor attention, and a defined plan for the next stage. The same company months later, after a milestone failure and with little cash left, presents a different credit problem. A loan raised at the right moment can preserve options. A loan raised to conceal that the company has run out of options can accelerate failure.
A lender is buying a way to understand the risk
The private-market evidence studied by Yael Hochberg, Carlos Serrano, and Rosemarie Ziedonis shows why venture lending can be more common than public databases suggest. Their sample covers 1,519 U.S. venture-capital-backed startups founded from 1987 through 1999 in software, semiconductor devices, and medical devices that received at least one patent. By 2008 or the company’s exit, 36% had secured a loan using patents. More than 25% of the patents awarded to the sample companies were involved in a security-interest agreement, and among borrowers an average of 92% of the patent portfolio was under lien by the final reported loan transaction year.
Those figures do not mean that every startup can borrow against a patent. The study observes a narrow channel: patent-backed security interests recorded with the U.S. Patent and Trademark Office. It does not capture every unsecured loan, every lien on other assets, insider bridge financing, or borrowing by startups without patents. It does show that the market is not an isolated curiosity. The lender is willing to transact when the company’s future value can be made more legible through several partial safeguards.
The first safeguard is the company’s future. A lender needs a story about what will generate repayment: a product launch, growing revenue, a next equity round, or another identifiable step. The second is recovery. A patent or another asset may be pledged so that default is not equivalent to total loss. A recorded security interest can establish the lender’s priority relative to other claimants, although priority does not guarantee that the asset will sell for enough to cover the loan. The third is the venture investor. A VC may have selected the company, helped monitor it, and retained an incentive to support it. That support can matter because a lender may expect the company to need another financing round before the loan matures.
The fourth safeguard is the contract itself. Maturity, repayment timing, performance-linked terms, security, warrants, and other conditions determine whether the company can survive long enough for its future value to appear. These mechanisms answer different questions. A longer maturity may reduce timing pressure, but it cannot create demand for a failed product. A patent lien may improve recovery, but it cannot replace management effort. A respected investor may improve confidence, but reputation alone cannot fund an exhausted company.
The right mental model is consequently not “lenders ignore the fact that startups lose money.” It is “lenders are willing to accept uncertain current cash flow when other evidence makes future repayment or loss recovery sufficiently credible.” The rest of this series examines those forms of evidence more closely, including what happens when a patent can be redeployed, what happens when an investor’s own funding becomes constrained, and what a public lender’s longer-term product changes. The next question is the most concrete one: when a startup pledges an intangible asset, what can the lender actually recover?